coo stock — COO (The Cooper Companies, Inc.)

COO (The Cooper Companies, Inc.) — Stock

coo stock is the ticker symbol used to identify The Cooper Companies, Inc. in public markets. The Cooper Companies operates primarily through two major business units — CooperVision (contact lenses) and CooperSurgical (women’s and fertility health). Note: this page discusses COO as an equity ticker (a company stock), not a cryptocurrency.

Company overview

The Cooper Companies, Inc. is a U.S.-based medical device and healthcare company that develops, manufactures and markets vision care products and women’s & fertility health solutions. The company’s two operating segments — CooperVision and CooperSurgical — serve global markets with contact lenses, lens care products, fertility services and surgical devices.

The business traces its roots back several decades and has grown through a mix of organic product development and targeted acquisitions to expand product lines and geographic reach. The company is headquartered in the United States and maintains manufacturing, R&D and commercial operations in multiple countries to serve global customers and clinical partners.

Ticker and listing information

Ticker: COO (the equity ticker for The Cooper Companies, Inc.).

Primary exchange and identifiers: COO is quoted and traded on major U.S. public markets and is tracked by common market-data providers. Investors use identifiers such as the ISIN and CUSIP (published in company filings and market data terminals) together with the ticker symbol when looking up the security. Typical U.S. equity trading hours apply (regular session 9:30 AM–4:00 PM ET; pre-market and after-hours sessions vary by venue and broker).

Where to confirm: For the official listing details — including the company’s exchange, ISIN, CUSIP and other identifiers — consult the company’s investor relations materials, SEC filings, or major financial data vendors.

Major business segments and products

CooperVision

CooperVision is the company’s contact lens business. It manufactures a broad range of soft contact lenses — including spherical daily- and monthly-wear lenses, toric lenses for astigmatism, multifocal lenses for presbyopia, and specialty lenses for conditions such as keratoconus or irregular corneas.

Product lines cover daily disposable lenses and monthly replacement lenses, with material and design innovations intended to address comfort, oxygen permeability, visual acuity and wearing schedules. CooperVision competes globally in retail and professional channels, supplying independent eye care professionals, multi-site optical practices and international distributors.

CooperSurgical

CooperSurgical focuses on women’s health and fertility-related products and services. The segment includes fertility solutions, in-vitro fertilization (IVF) tools and consumables, surgical instruments, IUDs and related devices. CooperSurgical also provides diagnostic tools, prenatal care devices and training/education resources for clinicians.

Strategically, CooperSurgical positions the company in growing markets for fertility and reproductive health, where demographic trends and expanded access to fertility care have supported demand growth in many regions.

Key brands and intellectual property

The Cooper Companies holds several notable consumer and clinical brands that are key revenue drivers. Examples include:

• Biofinity — a line of monthly replacement soft contact lenses known for material comfort and breathability.
• MyDay — daily disposable contact lens family designed for comfort and convenience.
• Proclear — contact lenses designed for users with specific comfort or hydration needs.
• Paragard — an intrauterine device (IUD) brand (note: product portfolios and ownership of specific device brands can change with strategic transactions; always verify current brand ownership in company disclosures).

These brands — together with registered patents, manufacturing know-how and distribution agreements — represent important intellectual property and commercial assets that contribute to market share and recurring revenue.

Financial overview and key metrics

Investors and analysts commonly monitor a set of core financial metrics to track COO performance. Typical metrics include:

• Market capitalization — total equity market value assigned by the market.
• Revenue and revenue growth — top-line sales by segment and geography.
• Net income and earnings per share (EPS) — profitability measures reported on a GAAP and adjusted basis.
• Valuation multiples — price/earnings (P/E), price/sales (P/S) and enterprise value ratios.
• Gross margin and operating margin — indicators of profitability at product and operational levels.
• Free cash flow and capital allocation metrics — cash generation available for dividends, buybacks and investments.

These figures are published in quarterly reports (Form 10-Q), annual reports (Form 10-K) and accompanying investor presentations. Trend analysis typically compares sequential quarters and year-over-year periods to identify growth drivers, margin trends and any one-time items that affect comparability.

Stock performance and historical price

coo stock price history is available via market-data providers and company investor pages. Investors examine:

• Historical price charts (daily, weekly, monthly) to assess volatility and trend.
• 52-week high and low and, where relevant, an all-time high.
• Total return, which includes price appreciation plus dividends and buybacks, where applicable.

Historical prices and total-return calculations are typically sourced from financial terminals, the exchange’s historical data, and data providers. For up-to-date charts and historical ranges, check market-data platforms and the company’s investor relations resource.

Dividends and capital returns

Cooper Companies’ capital allocation approach historically has included a mix of reinvestment in the business, targeted acquisitions and returns to shareholders where appropriate. Specific items to review include:

• Dividend policy — whether the company pays a regular cash dividend and any recent changes to payout levels.
• Share repurchase programs — announced buybacks, completed repurchases and remaining authorization.
• Special distributions or extraordinary returns of capital — if any.

Dividend history, yield and buyback announcements are disclosed in investor presentations, press releases and SEC filings. Note that companies may adjust distributions and buybacks based on cash flow, investment opportunities and board decisions.

Ownership and trading profile

Key aspects of COO’s ownership and trading profile that investors watch include:

• Institutional ownership — percentage of shares held by mutual funds, pension funds and other institutional investors.
• Insider ownership — holdings by executives and board members, and reported insider transactions.
• Shares outstanding and float — total shares issued and the free float available for trading.
• Average daily trading volume — a gauge of liquidity and how quickly large positions can be entered or exited.
• Inclusion in indices and ETFs — whether COO is held by sector or thematic ETFs, which can influence passive inflows.

These statistics are reported by market-data providers and often summarized in investor relations materials. Fund holdings and top holders are disclosed quarterly by institutions and can be found in public filings and provider databases.

Analysts, ratings and price targets

Brokerage research coverage and analyst consensus estimates provide commonly cited benchmarks for COO. Investors typically look at:

• Consensus ratings (buy/hold/sell) and summary distribution across the analyst community.
• Consensus earnings and revenue estimates for upcoming quarters and fiscal years.
• Analyst price targets and the range / median value among covering firms.

Up-to-date analyst coverage and consensus figures are available from financial news desks, data vendors and the company’s investor relations summary of analyst coverage. These tools can help investors understand market expectations, though they are not a substitute for independent research.

Corporate actions and material events

Several types of corporate actions and material events commonly move coo stock price and investor sentiment. These include:

• Earnings releases and management commentary during quarterly conference calls — particularly when guidance is introduced or revised.
• Mergers, acquisitions and divestitures that change segment mix, scale or product capabilities.
• Regulatory approvals or denials for medical devices and reproductive health products.
• New product launches, clinical data readouts or partnerships with healthcare providers.
• Changes to leadership, board composition or significant insider transactions that affect governance views.

Historically, earnings surprises (both positive and negative) and material regulatory news can produce sharp stock moves. Investors track press releases, SEC filings (8-Ks) and investor presentations to monitor these events as they are announced.

Risk factors affecting the stock

Principal investment risks for COO generally include the following categories. These are not exhaustive and should be read together with the company’s formal risk disclosures in SEC filings.

• Market competition: The contact lens and women’s health markets are competitive, with multiple large manufacturers and regional players vying for market share. Pricing pressures and product substitution can affect revenue and margin.
• Regulatory risks: Device approvals, regulatory compliance and reimbursement policies can materially affect product launches and sales. Changes in clinical or regulatory requirements can delay market access.
• Supply chain and operations: Manufacturing disruptions, material shortages, or quality control issues can impact product availability and costs.
• Currency and macro exposure: Global sales expose the company to foreign exchange movements and region-specific demand dynamics tied to macroeconomic conditions.
• Litigation and product liability: As a medical device company, litigation risk is present and may result in material costs or reputational impact.

These and other risks are summarized in the company’s annual report and must be reviewed by investors as part of due diligence.

Recent news and developments

To track recent developments affecting coo stock, follow the company’s press releases, quarterly earnings calls, and SEC filings. As of Jan. 27, 2026, according to financial press summaries and market coverage, the broader market environment was being influenced by mixed earnings results across sectors and a cautious rotation in investor appetite toward yield and commodity-linked assets. (Source: Yahoo Finance and Reuters reporting on the January 2026 earnings season and market themes.)

Because coo stock is driven by healthcare demand cycles, recent investor attention typically centers on quarterly results, product approvals and any strategic acquisitions or partnerships within fertility and vision-care spaces. Investors should monitor 8-Ks and other filings for timelier disclosure of material events.

Corporate governance

The Cooper Companies publishes governance documents, proxy statements and executive profiles that describe board structure, committee composition and executive compensation. Typical items covered in governance materials include:

• Board composition and independence standards.
• Key executives and roles (CEO, CFO, executive leadership) and short bios.
• Executive compensation frameworks and incentive plans.
• Shareholder meeting materials and proxy voting details.

Proxy statements (Form DEF 14A) and investor relations pages are the authoritative sources for governance and compensation disclosures.

How to research and trade COO

Researching coo stock effectively requires consulting primary sources and reliable market-data providers. Key sources and steps include:

• Review SEC filings — Forms 10-K, 10-Q and 8-K — for audited financials, risk factors and material event disclosure.
• Read the company’s investor relations presentations and the latest earnings transcript for management discussion and segment detail.
• Use market-data platforms (exchange pages, major financial data vendors and charting tools) to study price history, volume and valuation multiples.
• Check analyst reports and consensus estimates for context on expectations and coverage breadth.

When trading the stock, consider typical order types (market, limit, stop), liquidity and bid-ask spreads. For users choosing a trading venue, Bitget provides trading infrastructure and research tools designed for investors; review Bitget’s market access options, trading hours and fee schedule before placing trades. Remember: this is informational and not investment advice.

See also

• Contact lens industry overview
• Major competitors (examples in the vision-care and medical device space)
• Equity investing basics (valuation, risk management, diversification)
• ETFs and funds that include medical device or healthcare equities

References and external links

Primary and authoritative sources for coo stock information include the company’s investor relations page and SEC filings (10-K, 10-Q, 8-K). Market data and recent news coverage may be sourced from major financial outlets and market-data providers. For currency and date-sensitive context: as of Jan. 27, 2026, market coverage from major outlets summarized the start of the Q4/Q1 earnings season and sector rotations that affected equities broadly. (Sources: company filings, investor relations materials, Yahoo Finance, Reuters, and other market-data providers.)

To stay current, check the company’s latest filings and scheduled earnings releases and consult your trading venue’s market data for real-time quotes and charts.

Further exploration: Explore Bitget’s trading tools and research features to follow coo stock price action, review historical charts and set alerts. To learn more about the company’s strategy and recent filings, visit the company’s investor relations page and read their most recent Form 10-K and quarterly reports.